Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as ...

The global smart syringes market is poised for substantial growth, projected to escalate from a valuation of US$ 10.22 billion in 2024 to US$ 24.37 billion by 2033, reflecting an impressive CAGR of 10 ...

at an 85% discount off Stelara, and eligible patients may receive their medication at no cost or may be eligible for assistance through Teva’s programs. Selarsdi, approved by the FDA in October 2024, ...

Otulfi® is an ustekinumab biosimilar for the reference product Stelara® (ustekinumab ... in the U.S., is available in vial and prefilled syringe presentations. (Photo: Business Wire) Otulfi ...

Otulfi ® is an ustekinumab biosimilar for the reference product Stelara ® (ustekinumab ... a 45 mg/0.5 mL and 90 mg/mL single-dose prefilled syringe for injection and a 130 mg/26 mL (5 mg ...

announced today that the ustekinumab biosimilar Otulfi ® (ustekinumab-aauz) developed by Formycon AG, is now available in the United States. Otulfi ® is an ustekinumab biosimilar for the reference ...

FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United ... a 45 mg/0.5 mL and 90 mg/mL single-dose prefilled syringe for injection and a 130 mg/26 mL (5 mg/mL ...

The FDA has provisionally determined that Otulfi ® will be interchangeable with the reference drug Stelara ®, following ... 90 mg/mL single-dose prefilled syringe for injection and a 130 mg ...

Pyzchiva is supplied as a 45mg/0.5mL and a 90mg/mL single-dose prefilled syringe for subcutaneous (SC) injection, and a 130mg/26mL single-dose vial for intravenous (IV) infusion. According to Sandoz, ...

As a major component of the Connect 360 Autoimmune Program expansion, SmithRx will help employer clients and their employees adopt biosimilars, representing over 95% savings compared to Stelara ...